van Dalen EC, Raphaël MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2014;9:Cd006647. https://doi.org/10.1002/14651858.CD006647.pub4.

Article  Google Scholar 

van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):Cd005006. https://doi.org/10.1002/14651858.CD005006.pub4.

Article  PubMed  PubMed Central  Google Scholar 

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440–6. https://doi.org/10.1097/FPC.0b013e32833ffb56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–70. https://doi.org/10.1111/j.2042-7158.2012.01567.x.

Article  PubMed  CAS  Google Scholar 

Laboratories. B: Adriamycin (doxorubicin HCl) for injection. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/062921s022lbl.pdf. Accessed 26 July 2023.

Siebel C, Würthwein G, Lanvers-Kaminsky C, André N, Berthold F, Castelli I, et al. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacol Toxicol. 2020;21(1):37. https://doi.org/10.1186/s40360-020-00417-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

B.V. BH: summary of product characteristics doxorubicin. 1996. https://www.ema.europa.eu/en/documents/product-information/caelyx-pegylated-liposomal-epar-product-information_en.pdf. Accessed Jan 2024.

Routledge PA. Pharmacokinetics in children. J Antimicrob Chemother. 1994;34(Suppl A):19–24. https://doi.org/10.1093/jac/34.suppl_a.19.

Article  PubMed  Google Scholar 

Nijstad AL, Barnett S, Lalmohamed A, Bérénos IM, Parke E, Carruthers V, et al. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. Eur J Cancer. 2022;164:137–54. https://doi.org/10.1016/j.ejca.2021.11.001.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009;64(2):243–51. https://doi.org/10.1007/s00280-008-0854-z.

Article  PubMed  CAS  Google Scholar 

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, et al. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol. 2013;71(3):749–63. https://doi.org/10.1007/s00280-013-2069-1.

Article  PubMed  CAS  Google Scholar 

Völler S, Boos J, Krischke M, Würthwein G, Kontny NE, Boddy AV, et al. Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clin Pharmacokinet. 2015;54(11):1139–49. https://doi.org/10.1007/s40262-015-0272-4.

Article  PubMed  CAS  Google Scholar 

Kunarajah K, Hennig S, Norris RLG, Lobb M, Charles BG, Pinkerton R, et al. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? Cancer Chemother Pharmacol. 2017;80(1):15–25. https://doi.org/10.1007/s00280-017-3309-6.

Article  PubMed  CAS  Google Scholar 

Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of selected anticancer drugs in elderly cancer patients: focus on breast cancer. Cancers (Basel). 2016. https://doi.org/10.3390/cancers8010006.

Article  PubMed  PubMed Central  Google Scholar 

Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, et al. Exposure to docetaxel in the elderly patient population: a population pharmacokinetic study. Pharm Res. 2019;36(12):181. https://doi.org/10.1007/s11095-019-2706-4.

Article  PubMed  CAS  Google Scholar 

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46(12):1051–68. https://doi.org/10.2165/00003088-200746120-00005.

Article  PubMed  CAS  Google Scholar 

Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144(1):143–52. https://doi.org/10.1007/s10549-014-2843-8.

Article  PubMed  CAS  Google Scholar 

Dees EC, O’Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18(6):521–9. https://doi.org/10.3109/07357900009012191.

Article  PubMed  CAS  Google Scholar 

Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36(6):473–6. https://doi.org/10.1007/bf00685796.

Article  PubMed  CAS  Google Scholar 

Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51(5):395–402. https://doi.org/10.1007/s00280-002-0554-z.

Article  PubMed  CAS  Google Scholar 

(EMA). EMA: ICH Topic E11: clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). 2001. https://www.ema.europa.eu/en/documents/scientific-guideline/e-11-clinical-investigation-medicinal-products-paediatric-population-step-5_en.pdf. Accessed 19 Aug 2024.

(EMA). EMA: Committee for Human Medicinal Products (CHMP): adequacy of guidance on the elderly regardng medicinal products for human use. 2006. https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/adequacy-guidance-elderly-regarding-medicinal-products-human-use_en.pdf. Accessed 19 Aug 2024.

(FDA). FaDA: guideline for industry studies in support of special populations: geriatrics (ICHE7). 1994. https://www.fda.gov/media/71317/download-:~:text=IV.-,DEFINITION%20OF%20THE%20POPULATION,above%2C%20to%20the%20extent%20possible. Accessed 19 Aug 2024.

U.S. Department of Health and Human Services FaDAF, Center for Drug Evaluation and Research (CDER). General clinical pharmacology considerations for pediatric studies of drugs, including biological products guidance for industry (draft guidance). 2022. https://www.fda.gov/media/90358/download. Accessed 19 Aug 2024.

Eleveld DJ, Koomen JV, Absalom AR, Su H, Hannivoort LN, Struys M. Allometric scaling in pharmacokinetic studies in anesthesiology. Anesthesiology. 2022;136(4):609–17. https://doi.org/10.1097/aln.0000000000004115.

Article  PubMed  Google Scholar 

Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941–52. https://doi.org/10.1002/jps.23574.

Article  PubMed  CAS  Google Scholar 

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. Aaps J. 2011;13(2):143–51. https://doi.org/10.1208/s12248-011-9255-z.

Article  PubMed  PubMed Central  Google Scholar 

Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17–20. https://doi.org/10.1038/sj.clpt.6100241.

Article  PubMed  CAS  Google Scholar 

Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509–20. https://doi.org/10.1007/s10928-017-9542-0.

Article  PubMed  PubMed Central  Google Scholar 

Group. DCO: DCOG NBL 2009 treatment protocol, Amendment 1.1. 2015. https://www.skion.nl/richtlijn/dcog-nbl-2009/. Accessed Jan 2024.

Krischke M, Hempel G, Völler S, André N, D’Incalci M, Bisogno G, et al. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial. Cancer Chemother Pharmacol. 2016;78(6):1175–84. https://doi.org/10.1007/s00280-016-3174-8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Janssen JM, Van Calsteren K, Dorlo TPC, Halaska MJ, Fruscio R, Ottevanger P, et al. Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the international network of cancer, infertility and pregnancy (INCIP). Clin Pharmacokinet. 2021;60(6):775–84. https://doi.org/10.1007/s40262-020-00961-4.

Article  PubMed